123 related articles for article (PubMed ID: 28087305)
21. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
Goulart BH; Clark JW; Lauwers GY; Ryan DP; Grenon N; Muzikansky A; Zhu AX
J Hematol Oncol; 2009 Mar; 2():13. PubMed ID: 19291303
[TBL] [Abstract][Full Text] [Related]
22. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
Halm U; Schumann T; Schiefke I; Witzigmann H; Mössner J; Keim V
Br J Cancer; 2000 Mar; 82(5):1013-6. PubMed ID: 10737382
[TBL] [Abstract][Full Text] [Related]
23. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.
Boone BA; Bahary N; Zureikat AH; Moser AJ; Normolle DP; Wu WC; Singhi AD; Bao P; Bartlett DL; Liotta LA; Espina V; Loughran P; Lotze MT; Zeh HJ
Ann Surg Oncol; 2015 Dec; 22(13):4402-10. PubMed ID: 25905586
[TBL] [Abstract][Full Text] [Related]
24. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
Miyahara K; Nouso K; Morimoto Y; Kinugasa H; Kato H; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Nakahara T; Miura Y; Asada H; Amano M; Nishimura S; Yamamoto K
Pancreas; 2015 May; 44(4):551-6. PubMed ID: 25875794
[TBL] [Abstract][Full Text] [Related]
26. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
27. [Clinical features of long time survivors with unresectable pancreatic cancer treated by gemcitabine alone].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Fujisawa N; Yoneda M; Abe Y; Inamori M; Kawamura H; Kirikoshi H; Shimamura T; Kubota K; Sakaguchi T; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2006 Feb; 33(2):207-12. PubMed ID: 16484857
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.
Park I; Choi SJ; Kim YS; Ahn HK; Hong J; Sym SJ; Park J; Cho EK; Lee JH; Shin YJ; Shin DB
Cancer Res Treat; 2016 Oct; 48(4):1264-1273. PubMed ID: 27034148
[TBL] [Abstract][Full Text] [Related]
29. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
[TBL] [Abstract][Full Text] [Related]
30. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Gourgou-Bourgade S; Bascoul-Mollevi C; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Boige V; Bérille J; Conroy T
J Clin Oncol; 2013 Jan; 31(1):23-9. PubMed ID: 23213101
[TBL] [Abstract][Full Text] [Related]
31. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
32. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
[TBL] [Abstract][Full Text] [Related]
33. Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study.
Oberstein PE; Hershman DL; Khanna LG; Chabot JA; Insel BJ; Neugut AI
Cancer Invest; 2013 Jun; 31(5):316-22. PubMed ID: 23614655
[TBL] [Abstract][Full Text] [Related]
34. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
[TBL] [Abstract][Full Text] [Related]
35. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
36. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Rabbi C; Marangolo M
J Chemother; 2004 Dec; 16(6):589-94. PubMed ID: 15700852
[TBL] [Abstract][Full Text] [Related]
38. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.
Li D; Pant S; Ryan DP; Laheru D; Bahary N; Dragovich T; Hosein PJ; Rolfe L; Saif MW; LaValle J; Yu KH; Lowery MA; Allen A; O'Reilly EM
Pancreatology; 2014; 14(5):398-402. PubMed ID: 25278310
[TBL] [Abstract][Full Text] [Related]
39. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial.
Sakamoto H; Kitano M; Suetomi Y; Takeyama Y; Ohyanagi H; Nakai T; Yasuda C; Kudo M
J Gastroenterol; 2006 Jan; 41(1):70-6. PubMed ID: 16501860
[TBL] [Abstract][Full Text] [Related]
40. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
